Posts

Strengthening Mycoplasma Control in GMP Viral Vector Manufacturing

Image
  Viral vectors play an essential role in modern cell and gene therapy, enabling researchers and manufacturers to deliver genetic material into target cells. However, maintaining product quality throughout production requires strict contamination control. Mycoplasma presents a particular challenge because these microorganisms can enter cell cultures without causing obvious changes in appearance or growth. Effective mycoplasma viral vector manufacturing practices help manufacturers protect cell culture integrity, maintain process consistency, and support the production of safe, high-quality viral vector products. As viral vector manufacturing advances toward clinical and commercial applications, manufacturers must integrate contamination prevention, appropriate testing, and documented quality controls into their production strategies. A proactive approach helps identify potential risks early and supports compliance with applicable Good Manufacturing Practice (GMP) requirements. Und...
Post a Comment
Read more

Cell Therapy Process Development: From Process Optimization to Tech Transfer

Image
Cell therapies are transforming modern medicine by using living cells to repair, replace, or modify biological functions. However, moving a promising cell therapy from laboratory research toward clinical manufacturing requires much more than demonstrating biological activity. Developers must establish robust, reproducible, scalable, and controlled manufacturing processes that consistently deliver the desired product. This is where cell therapy process development becomes essential. A well-designed development strategy connects early research with manufacturing, quality control, regulatory expectations, and eventual technology transfer. From process optimization to scale-up and tech transfer, every stage helps create a manufacturing process that can support clinical and commercial objectives. What Is Cell Therapy Process Development? Cell therapy process development involves designing, evaluating, and optimizing the manufacturing steps used to produce a consistent cell-based therapeuti...
Post a Comment
Read more

How CDMO Partnerships Can Accelerate Cell and Gene Therapy Commercialization

Image
Moving a cell or gene therapy from clinical development toward commercial supply requires coordination across process development, manufacturing, analytical testing, quality, regulatory readiness, and supply chain planning. Managing these activities internally can create significant operational and technical demands for biotechnology and pharmaceutical companies. Strategic end to end CDMO services can help developers bring these capabilities together under a coordinated manufacturing strategy. Instead of managing multiple specialized suppliers and internal functions independently, developers can work with a partner that supports several stages of the product lifecycle. For cell and gene therapy programs, this integrated model can improve continuity, simplify technology transfer, and help development teams prepare earlier for commercial manufacturing requirements. Why Commercialization Is Complex for Cell and Gene Therapies Cell and gene therapies have manufacturing requirements that d...
Post a Comment
Location: Hong Kong
Read more